DNMT3A and acute myeloid leukemia: Mutant DNMT3A did not display any impact on survival when the study cohort included all the patients, but a significantly unfavorable impact on OS of mutant DNMT3A could be observed in CN‐AML (2‐year OS: 44.3% vs 60.9%, P = .024; Figure S4C).